Shanghai Allist Pharmaceuticals Co., Ltd. (SHA: 688578)
China
· Delayed Price · Currency is CNY
56.37
+5.85 (11.58%)
Nov 20, 2024, 3:00 PM CST
Shanghai Allist Pharmaceuticals Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
Net Income | 1,297 | 644.17 | 130.52 | 18.27 | -310.52 | -397.5 | Upgrade
|
Depreciation & Amortization | 39.39 | 39.39 | 25.25 | 23.46 | 11.86 | 9.54 | Upgrade
|
Other Amortization | 0.79 | 0.79 | 1.77 | 2.42 | 0.63 | - | Upgrade
|
Loss (Gain) From Sale of Assets | -0.02 | -0.02 | -0.03 | - | - | 0.03 | Upgrade
|
Asset Writedown & Restructuring Costs | 0.03 | 0.03 | 1.71 | -34.53 | 0.02 | - | Upgrade
|
Loss (Gain) From Sale of Investments | -32.58 | -32.58 | -45.01 | -66.01 | -23.7 | -17.58 | Upgrade
|
Stock-Based Compensation | - | - | - | - | 71.62 | 201.2 | Upgrade
|
Provision & Write-off of Bad Debts | -0.71 | -0.71 | 1.36 | 0.5 | -0.02 | 0 | Upgrade
|
Other Operating Activities | 86.08 | -36.02 | -29.53 | 4.72 | 1.19 | 7.23 | Upgrade
|
Change in Accounts Receivable | -163.84 | -163.84 | -108.57 | 8.22 | -1.3 | -38.57 | Upgrade
|
Change in Inventory | -30.88 | -30.88 | -10.62 | -12.34 | -10.53 | -0.21 | Upgrade
|
Change in Accounts Payable | 184.14 | 184.14 | 67.38 | 10.89 | 64.01 | -23.51 | Upgrade
|
Change in Other Net Operating Assets | 75.03 | 75.03 | 68.91 | 73.69 | - | - | Upgrade
|
Operating Cash Flow | 1,449 | 674.65 | 91.63 | 29.29 | -196.75 | -259.37 | Upgrade
|
Operating Cash Flow Growth | 178.91% | 636.28% | 212.82% | - | - | - | Upgrade
|
Capital Expenditures | -230.05 | -67.88 | -143.83 | -192.25 | -88.45 | -89.37 | Upgrade
|
Sale of Property, Plant & Equipment | - | - | 0 | - | - | - | Upgrade
|
Investment in Securities | 1,418 | 1,418 | 81.63 | 599.99 | -1,671 | -550 | Upgrade
|
Other Investing Activities | -2,855 | -1,257 | -342.02 | -168.56 | 16.67 | 16.95 | Upgrade
|
Investing Cash Flow | -1,667 | 92.75 | -404.21 | 239.19 | -1,743 | -622.42 | Upgrade
|
Long-Term Debt Issued | - | - | - | - | - | 20 | Upgrade
|
Total Debt Issued | - | - | - | - | - | 20 | Upgrade
|
Short-Term Debt Repaid | - | - | - | - | - | -61.65 | Upgrade
|
Long-Term Debt Repaid | - | -2.58 | -4.87 | -8.97 | -110 | -35 | Upgrade
|
Total Debt Repaid | -2.58 | -2.58 | -4.87 | -8.97 | -110 | -96.65 | Upgrade
|
Net Debt Issued (Repaid) | -2.58 | -2.58 | -4.87 | -8.97 | -110 | -76.65 | Upgrade
|
Issuance of Common Stock | - | - | - | - | 1,943 | 1,391 | Upgrade
|
Common Dividends Paid | -292.5 | - | - | - | -1.19 | -33.38 | Upgrade
|
Other Financing Activities | 0.33 | 0.37 | 1.19 | -8 | 80.91 | -128.3 | Upgrade
|
Financing Cash Flow | -294.75 | -2.21 | -3.69 | -16.97 | 1,913 | 1,152 | Upgrade
|
Foreign Exchange Rate Adjustments | -1.36 | 4.35 | 17.17 | -3.38 | -0.35 | -1.09 | Upgrade
|
Net Cash Flow | -514.28 | 769.55 | -299.1 | 248.13 | -26.74 | 269.59 | Upgrade
|
Free Cash Flow | 1,219 | 606.77 | -52.21 | -162.95 | -285.2 | -348.74 | Upgrade
|
Free Cash Flow Margin | 38.05% | 30.07% | -6.60% | -30.74% | -50847.96% | -55379.94% | Upgrade
|
Free Cash Flow Per Share | 2.71 | 1.35 | -0.12 | -0.36 | -0.77 | -0.97 | Upgrade
|
Cash Income Tax Paid | 450.74 | 243.72 | 12.82 | -15.03 | 2.73 | 32.57 | Upgrade
|
Levered Free Cash Flow | 717.91 | 379.14 | -56.71 | -120.89 | -204.99 | -220.76 | Upgrade
|
Unlevered Free Cash Flow | 717.99 | 379.24 | -56.5 | -120.51 | -204.28 | -215.9 | Upgrade
|
Change in Net Working Capital | -37.32 | 11.57 | 32.75 | -15.79 | -26.16 | 89.98 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.